Search Orphan Drug Designations and Approvals
-
Generic Name: | APG-2575, a novel, orally active, selective and potent BCL-2 inhibitor |
---|---|
Date Designated: | 10/14/2020 |
Orphan Designation: | Treatment for multiple myeloma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Ascentage Pharma Group Inc. 700 King Farm Blvd., Suite 510 Rockville, Maryland 20850 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-